Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

4.410 +0.370 (+9.16%)
Streaming Delayed Price Updated: 3:23 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Ironwood (IRWD) Q4 2025 Earnings Call Transcript ↗
Ironwood (IRWD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Reports Q4 Miss but Provides Robust 2026 Outlook ↗
Via Chartmill
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Fits the Minervini High-Growth Momentum Trend Template ↗
Via Chartmill
News headline image
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Stocks Trading Near $5 With Massive Earnings Upside ↗
Via MarketBeat
News headline image
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating ↗
Via MarketBeat
Discover the most active stocks in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? ↗
The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range. 
Via Stocktwits
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-10: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Top movers in Monday's session ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Monday's pre-market session: top gainers and losers ↗
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharma Stock Soars After FDA Grants Approval For Irritable Bowel Syndrome Drug In Pediatric Patients ↗
Linzess is the first treatment approved for the disease in pediatric patients, the FDA said. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Why American Eagle Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Ironwood (IRWD) Q2 EPS Jumps 600% ↗
Via The Motley Fool
News headline image
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Reports Strong Q2 2025 Earnings with 37.5% Revenue Beat and 250% EPS Surge ↗
Ironwood Pharmaceuticals Q2 2025 earnings beat estimates with $85.24M revenue and $0.14 EPS, driven by LINZESS growth and pipeline progress. Shares surged 19.25% pre-market. 
Via Chartmill
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.